✦ LIBER ✦

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

✍ Scribed by Weinstock-Guttman, Bianca; Galetta, Steven L.; Giovannoni, Gavin; Havrdova, Eva; Hutchinson, Michael; Kappos, Ludwig; O’Connor, Paul W.; Phillips, J. Theodore; Polman, Chris; Stuart, William H.

Book ID: 113040371
Publisher: Springer
Year: 2011
Tongue: English
Weight: 290 KB
Volume: 259
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-011-6275-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of natalizumab in second line t

Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries

✍ N. Putzki; O. Yaldizli; M. Mäurer; S. Cursiefen; S. Kuckert; C. Klawe; M. Maschk 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

FP33-WE-02 Efficacy of natalizumab in se

FP33-WE-02 Efficacy of natalizumab in second-line therapy of relapsing remitting multiple sclerosis: results from a multi-center study in German speaking countries

✍ N. Putzki; Y. Oezguer; M. Mäurer; S. Cursiefen; S. Kuckert; V. Limmroth; M. Masc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

OPL102 Subgroup analyses from SENTINEL:

OPL102 Subgroup analyses from SENTINEL: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Reduction in magnetic resonance imaging

Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study

✍ A Traboulsee; A AL-Sabbagh; R Bennett; P Chang; DKB Li; the EVIDENCE Study Group 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 331 KB